GIT 27 – 5 mg

Brand:
Cayman
CAS:
6501-72-0
Storage:
-20
UN-No:
Non-Hazardous - /

GIT 27 is an orally active, isoxazole compound that exhibits various immunomodulatory properties both in vitro and in preclinical in vivo models of autoimmune diseases by inhibiting inflammatory antigen presentation.{30814} It has been shown to target macrophages, reducing the production of the proinflammatory mediators TNF-α, IL-1β, macrophage migration inhibitory factor, and inducible nitric oxide synthase-mediated nitric oxide generation in both pancreatic islets and peripheral compartments.{30815} GIT 27 can also prevent IL-1β/interferon-γ-induced pancreatic islet death in vitro at 10 µg/ml and reduce the cumulative incidence of diabetes and insulitis in a mouse model of type 1 diabetes at 20 mg/kg.{30815}  

 

SKU: - Category:

Description

An immunomodulatory compound that inhibits inflammatory antigen presentation both in vitro and in preclinical in vivo models of autoimmune diseases; targets macrophages, reducing the production of the proinflammatory mediators TNF-α, IL-1β, macrophage migration inhibitory factor, and inducible nitric oxide synthase-mediated nitric oxide generation


Formal name: 4,​5-​dihydro-​3-​phenyl-5-​isoxazoleacetic acid

Synonyms:  VGX-1027

Molecular weight: 205.2

CAS: 6501-72-0

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals||Research Area|Immunology & Inflammation|Autoimmunity||Research Area|Immunology & Inflammation|Innate Immunity